About ONCODESIGN

Company Description

Founded in 1995 by Dr Philippe Genne, the Company’s CEO and Chairman, Oncodesign is a biopharma company dedicated to the precision medicine.

With its unique experience acquired by working with more than 600 clients, including the world’s largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis and medical imaging, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug.

Applied to kinase inhibitors, which represent a market estimated at over $46 billion in 2016 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB

Year founded

1995

Served area

Worldwide

Headcount

230

Headquarters

18 Rue Jean Mazen, 21000 Dijon – France

Shareholder information

Shares outstanding

6,848,412

IPO

April 2, 2014

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.